Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
IPO Year: 2021
Exchange: NASDAQ
Website: recursion.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/22/2023 | $8.00 | Equal-Weight | Morgan Stanley |
3/16/2023 | $17.00 | Buy | Needham |
9/16/2022 | $20.00 | Overweight | KeyBanc Capital Markets |
4/18/2022 | $10.00 | Buy → Neutral | BofA Securities |
3/4/2022 | $32.00 → $10.00 | Outperform → Market Perform | SVB Leerink |
12/8/2021 | $30.00 → $32.00 | Outperform | SVB Leerink |
9/21/2021 | $37.00 | Buy | Berenberg |
8/16/2021 | $33.00 → $30.00 | Outperform | SVB Leerink |
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership. "I'm excited to bring my clinical and scientific expertise to support Recursion's growth as Chair of the Board," said Dr. Hershberg. "In my opinion, the intersection of scientific rigor and technology to drive novel programs is the future of drug discovery and I believe Recursion will be a leader in this emerging sp
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion's research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion's Board of Directors. "Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business," said Chris Gibson, Co-Founder and CEO of Recursion. "More importantly, she has a vision and passion for transforming drug disco
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London's vibrant King's Cross neighborhood. Set to formally open in June 2024, the site will provide Recursion and Valence Labs, the company's artificial intelligence research engine, access to world-class talent across Europe's rapidly growing TechBio sector and embed Recursion in a thriving innovation ecosystem of leading technology and life science companies. "As Recursion continues to lead and define the TechBio industry, it's critical we hire the best possible talent, much of which
SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer. Dr. Mauro will lead Recursion's pipeline into and through clinical development, including its five programs currently in the clinic, beginning June 1. "We are incredibly excited to have Dr. Mauro join our team at Recursion at such an important time in the development of our clinical pipeline," said Chris Gibson, Ph.D., Co-founder and CEO at Recursion. "With his extensive background in oncology drug development and a proven track record of
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an additional 4,615,384 shares of its Class A common stock. Before deducting the underwriting discounts and commissions and estimated offering expenses, Recursion expects to receive total gross proceeds o
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock offered. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the off
Access to Helix's large-scale clinico-genomic data to drive creation and training of AI models Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to industrialize drug discovery. Recursion will have access to de-identified clinico-genomic data, collected from research participants who consent to participate in Helix's extensive research network, which includes health systems from across the US. These population-scale cohorts, consisting of full longitudinal clinical records paired wi
Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nominationBayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, analysts, and other stakeholders during Download Day, Recursion's investor and R&D day, on Monday, June 24, 2024. "Since our last Download Day, which was approximately 18 months ago, we have
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Jefferies Healthcare Conference - June 5-6, 2024 45th Annual Goldman Sachs Healthcare Conference - June 10-13, 2024 Morgan Stanley 3rd Annual Life Sciences AI Summit - June 26-27, 2024 About Recursion Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the w
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. This proximity bias, discoverable through Recursion's proprietary biological dataset, could have many downstream impacts on the community's ability to make meaningful progress in our understanding and treatment of disease within both large scale datasets and small gene-specific work. CRISPR-Cas9 is a rev
SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership. "I'm excited to bring my clinical and scientific expertise to support Recursion's growth as Chair of the Board," said Dr. Hershberg. "In my opinion, the intersection of scientific rigor and technology to drive novel programs is the future of drug discovery and I believe Recursion will be a leader in this emerging sp
SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of BioHive-2, Recursion's new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 DGX H100 systems with a total of 504 NVIDIA H100 Tensor Core GPUs interconnected by NVIDIA Quantum-2 InfiniBand networking. This NVIDIA-powered AI supercomputer results in four times faster speeds than Recursion's original supercomputer, BioHive-1, in benchmark performance tests. Based on available data, BioHive-2 is the fastest supercomputer wholly owned and operated by any pharmaceutical company worldwide. "Scale
On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will support the construction of foundation models across biology, chemistry, and patient outcomesTranscriptomics technology has continued to be scaled to more than 1 million transcriptomes with a whole-genome knockout transcriptomics map to be completed in the coming quartersEntered into a multi-year agreement with Helix to access hundreds of thousands of de-identified records for training causal AI models and designing biomarker and patient stratification strategies SALT LAKE CITY, May 09, 2024
SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on Thursday, May 9, 2024, following the close of the financial markets. Additionally, Recursion will host its quarterly L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time. A L(earnings) Call is Recursion's take on interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion's X (for
Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00
Needham initiated coverage of Recursion Pharmaceuticals with a rating of Buy and set a new price target of $17.00
KeyBanc Capital Markets initiated coverage of Recursion Pharmaceuticals with a rating of Overweight and set a new price target of $20.00
BofA Securities downgraded Recursion Pharmaceuticals from Buy to Neutral and set a new price target of $10.00
SVB Leerink downgraded Recursion Pharmaceuticals from Outperform to Market Perform and set a new price target of $10.00 from $32.00 previously
SVB Leerink reiterated coverage of Recursion Pharmaceuticals with a rating of Outperform and set a new price target of $32.00 from $30.00 previously
Berenberg initiated coverage of Recursion Pharmaceuticals with a rating of Buy and set a new price target of $37.00
SVB Leerink reiterated coverage of Recursion Pharmaceuticals with a rating of Outperform and set a new price target of $30.00 from $33.00 previously
SVB Leerink initiated coverage of Recursion Pharmaceuticals with a rating of Outperform and set a new price target of $33.00
JP Morgan initiated coverage of Recursion Pharmaceuticals with a rating of Neutral and set a new price target of $32.00
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Technologies Inc (NYSE:PLTR). The Tesla Trade Ark Invest reduced its stake in Tesla across two of its ETFs — ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW). The firm sold 56,425 and 6,442 shares respectively, the transaction was valued at $14.54 million. On Tuesday, Tesla shares closed 10.2% higher at $231.26, driven higher by the second-quarter delivery report of the company. The numbers came ahead of the consensus estimate. This move comes despite Wood’s
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum. The PLTR Trade Ark Invest, through its ARK Autonomous Technology & Robotics ETF (BATS:ARKQ), purchased 199,372 shares of Palantir, a significant addition to its portfolio. The value of this trade, based on the closing price of $25.88 on the same day, stands at approximately $5.16 million. Palantir has recently been praised as an ‘AI Halo’ play by momentum investors. The company was added to BofA Securities’ top 10 best U.S. ideas list for the third quarter, highlighting its growing popularity in the AI sector. Joe Terranova of V
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Thursday after the company announced a proposed offering of its common stock. What Happened: Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwritten public offering. The clinical-stage biotech company also said it plans to grant the underwriters a 30-day option to purchase up to an additional 4,615,384 of the shares being offered. All of the shares are being sold by Recursion. Recursion expects to receive total gross proceeds of approximately $200 million. The offering is expected to close on or about June 28. Recursion had $296.3 million i
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Proposal To Acquire Its China Business For Aggregate Purchase Price Of $40M MEDS: 34% | TRxADE HEALTH shares are trading higher. The company reported Q1 financial results. RXRX: -21% | Recursion Pharmaceuticals Announced The Pricing Of Its Underwritten Public Offering Of 30,769,230 Shares Of Its Class A Common Stock At A Price To The Public Of $6.50 Per Share
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday. Shares of Levi Strauss & Co. (NYSE:LEVI) fell sharply in today’s pre-market trading after the company reported mixed second-quarter financial results and issued FY24 EPS guidance with its midpoint below estimates. Levi Strauss reported quarterly earnings of 16 cents per share which beat the analyst consensus estimate of 11 cents by 45.45%. Quarterly sales came in at $1.44 billion, missing the analyst consensus estimate of $1.45 billion. Levi Strauss shares dipped 16.1% to $19.40 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower in Wednesday’s after-hours session after the company announced a proposed offering of its common stock. What Happened: After the market close on Wednesday, Recursion said it intends to offer and sell $200 million worth of its common stock in an underwritten public offering. All of the shares are being offered by Recursion. The clinical-stage biotech company also said it plans to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares being offered. Recursion had $296.3 million in cash and cash equivalents as of March 31. The proposed offering comes just days after Recursion held
424B5 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
424B5 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
DEFA14A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
S-8 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
10-Q - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on Thursday, May 9, 2024, following the close of the financial markets. Additionally, Recursion will host its quarterly L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time. A L(earnings) Call is Recursion's take on interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion's X (for
USA News Group Commentary VANCOUVER, BC, April 25, 2024 /PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the largest boost. According to a new research report from analysts at Mordor Intelligence, the market for artificial intelligence in health care is set to explode at a CAGR of 42.20% through 2029. As the tech sector races to provide the market with solutions, several companies are emerging as leaders in aiding the healthcare sector, including Avant Technologies Inc. (OTC:AVAI), Microsoft Corporation (NASDAQ:MSFT) (NEO:MSFT), Health Catalyst, Inc. (NASDAQ:HCAT), Ginkgo Bioworks Holdings,
SALT LAKE CITY, July 1, 2021 /PRNewswire/ -- Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that it is doubling the size of its headquarters at The Gateway in downtown Salt Lake City, signing a new lease with Vestar for an additional 100,000 square feet. The Gateway is a mixed-use lifestyle and entertainment district, featuring 1.2 million square feet of retail, dining and office space as well as 1,200 multifamily units.